HaloLaser Biotherapy, LLC Has Signed A Letter Of Intent To Acquire The Assets Of FHJ Scientific, Inc., To Be Included In Merger Agreement With Corbel Holdings Inc.

DALLAS, Nov. 9 /PRNewswire-FirstCall/ -- HaloLaser Biotherapy, LLC, is pleased to announce the signing of a letter of intent to acquire the assets of FHJ Scientific, Inc., for $1.2 million in stock, to be included in the merger agreement with Corbel Holdings Inc. (Pink Sheets: CBLH). The purchase includes five Letters of Patent, together with several foreign patents and/or patents pending and other assets of FHJ.

FHJ is a privately held Texas corporation, which was formed in 1985. FHJ has the proprietary SHBAN(TM) Solution. In vitro and other testing have demonstrated the capabilities and superiority of SHBAN over known commercial products in applications covering contact dermatitis, dermal wounds and burns, ophthalmic and oral care. An example of the efficacy of the SHBAN Solution is its ability to quickly heal gingivitis.

HaloLaser Biotherapy LLC, and Charles R. Crane MD and Associates Inc., announced earlier that they were to enter an agreement to facilitate a reverse merger of HaloLaser Biotherapy LLC and Charles R. Crane MD and Associates into Corbel Holdings, Inc. for purposes of taking control and functioning on its own merits and being identified as a legal trading company. Corbel Holdings, Inc., HaloLaser Biotherapy LLC, and Charles R. Crane MD and Associates Inc. have remaining a 20-day due diligence period before the closing of the transaction.

HaloLaser Biotherapy LLC in Dallas, Texas is in the biotech medical healthcare business of treating patients with acute pain and arthritis with the new FDA approved Neurolase 150 Medical laser device.

Delton Carrall, President and CEO of FHJ stated: "I believe once the SHBAN product or a derivative thereof is in the marketplace, it will sell itself due to the products superiority. We of FHJ are excited that the potential merger of HaloLaser with Corbel and the asset acquisition of FHJ will help get SHBAN to market more quickly."

Keith Houser, President and CEO of HaloLaser stated, "I have used the SHBAN oral and skin solution and was amazed as to its healing ability. It's exciting providing an opportunity to bring a new technology to improve one's quality of life." Additional information on HaloLaser can be found on the Internet at http://www.halolaser.com/ .

Bruce Harlan, President and CEO of Corbel Holdings, Inc., stated, "We are very excited to have the assets of FHJ Scientific, Inc., Halo Laser and Charles R. Crane MD and Associates Inc., merge into Corbel Holdings and expect to have the transaction closed before the end of this month."

Safe Harbor:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "scheduled," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the Company to complete the planned bridge financing, market conditions, the general acceptance of the Company's products and technologies, competitive factors, timing and other risks described in the Company's SEC reports and filings.

Contacts: Bruce Harlan of Corbel Holdings, Phone: +1-702-326-2805, or Keith Houser of HaloLaser Biotherapy LLC, Toll Free: 800-200-2458

CONTACT: Bruce Harlan of Corbel Holdings Inc., +1-702-326-2805; or KeithHouser of HaloLaser Biotherapy LLC, 800-200-2458

Web site: http://www.halolaser.com/